MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/infdis/jiac445

Медицинская библиотека · The Journal of infectious diseases · 2023

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.

Stieh Daniel J, Barouch Dan H, Comeaux Christy, Sarnecki Michal, Stephenson Kathryn E, Walsh Stephen R, Sawant Sheetal, Heptinstall Jack, Tomaras Georgia D, Kublin James G, McElrath M Juliana, Cohen Kristen W, De Rosa Stephen C, Alter Galit, Ferrari Guido, Montefiori David, Mann Philipp, Nijs Steven, Callewaert Katleen, Goepfert Paul A, Edupuganti Srilatha, Karita Etienne, Seaman Michael S, Corey Lawrence, Baden Lindsey R, Pau Maria G, Schuitemaker Hanneke, Tomaka Frank, ASCENT/HVTN118/HPX2003 Study Team

Клиническое исследование I фазыКлиническое исследование II фазыСтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПоддержка правительства СШАПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Developing a cross-clade, globally effective HIV vaccine remains crucial for eliminating HIV.

METHODS

This placebo-controlled, double-blind, phase 1/2a study enrolled healthy HIV-uninfected adults at low risk for HIV infection. They were randomized (1:4:1) to receive 4 doses of an adenovirus 26-based HIV-1 vaccine encoding 2 mosaic Gag and Pol, and 2 mosaic Env proteins plus adjuvanted clade C gp140 (referred to here as clade C regimen), bivalent protein regimen (clade C regimen plus mosaic gp140), or placebo. Primary end points were safety and antibody responses.

RESULTS

In total 152/155 participants (clade C, n = 26; bivalent protein, n = 103; placebo, n = 26) received ≥1 injection. The highest adverse event (AE) severity was grade 3 (local pain/tenderness, 12%, 2%, and 0% of the respective groups; solicited systemic AEs, 19%, 15%, 0%). HIV-1 mosaic gp140-binding antibody titers were 79 595 ELISA units (EU)/mL and 137 520 EU/mL in the clade C and bivalent protein groups (P < .001) after dose 4 and 16 862 EU/mL and 25 162 EU/mL 6 months later. Antibody response breadth against clade C gp140 and clade C/non-clade C gp120 was highest in the bivalent protein group.

CONCLUSIONS

Adding mosaic gp140 to the clade C regimen increased and broadened the elicited immune response without compromising safety or clade C responses. Clinical Trials Registration. NCT02935686.

Для цитирования: Stieh Daniel J, Barouch Dan H, Comeaux Christy, Sarnecki Michal, Stephenson Kathryn E, Walsh Stephen R, Sawant Sheetal, Heptinstall Jack, Tomaras Georgia D, Kublin James G, McElrath M Juliana, Cohen Kristen W, De Rosa Stephen C, Alter Galit, Ferrari Guido, Montefiori David, Mann Philipp, Nijs Steven, Callewaert Katleen, Goepfert Paul A, Edupuganti Srilatha, Karita Etienne, Seaman Michael S, Corey Lawrence, Baden Lindsey R, Pau Maria G, Schuitemaker Hanneke, Tomaka Frank, ASCENT/HVTN118/HPX2003 Study Team. Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.. The Journal of infectious diseases. 2023. DOI: 10.1093/infdis/jiac445.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.